Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 517493, 8 pages
http://dx.doi.org/10.1155/2010/517493
Review Article

Dendritic Cell-Based Immunotherapy for Prostate Cancer

1Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, Germany
2Department of Urology, Medical Faculty, Technical University of Dresden, 01307 Dresden, Germany
3Translational Sciences and Safety, Novartis Biologic, 4002 Basel, Switzerland
4Center for Regenerative Therapies Dresden, 01307 Dresden, Germany

Received 30 June 2010; Accepted 7 October 2010

Academic Editor: Yang Liu

Copyright © 2010 Hanka Jähnisch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle, “Estimates of the cancer incidence and mortality in Europe in 2006,” Annals of Oncology, vol. 18, no. 3, pp. 581–592, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. Heidenreich, G. Aus, M. Bolla et al., “EAU guidelines on prostate cancer,” European Urology, vol. 53, no. 1, pp. 68–80, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J.-E. Damber and G. Aus, “Prostate cancer,” The Lancet, vol. 371, no. 9625, pp. 1710–1721, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. A. Roehl, M. Han, C. G. Ramos, J. A. V. Antenor, and W. J. Catalona, “Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results,” The Journal of Urology, vol. 172, no. 3, pp. 910–914, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J.-B. Lattouf and F. Saad, “Bone complications of androgen deprivation therapy: screening, prevention, and treatment,” Current Opinion in Urology, vol. 20, no. 3, pp. 247–252, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. M. R. Smith, B. Egerdie, N. H. Toriz et al., “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” The New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at PubMed
  8. I. F. Tannock, R. De Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. M. Steinman and J. Banchereau, “Taking dendritic cells into medicine,” Nature, vol. 449, no. 7161, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. A. Rosenberg, “Cancer vaccines based on the identification of genes encoding cancer regression antigens,” Immunology Today, vol. 18, no. 4, pp. 175–182, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. S. A. Rosenberg and M. E. Dudley, “Adoptive cell therapy for the treatment of patients with metastatic melanoma,” Current Opinion in Immunology, vol. 21, no. 2, pp. 233–240, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R.-F. Wang, “The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity,” Trends in Immunology, vol. 22, no. 5, pp. 269–276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. N. C. Fernandez, A. Lozier, C. Flament et al., “Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo,” Nature Medicine, vol. 5, no. 4, pp. 405–411, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Ferlazzo, M. L. Tsang, L. Moretta, G. Melioli, R. M. Steinman, and C. Münz, “Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells,” The Journal of Experimental Medicine, vol. 195, no. 3, pp. 343–351, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Wehner, B. Löbel, M. Bornhäuser et al., “Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells,” International Journal of Cancer, vol. 124, no. 2, pp. 358–366, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. N. A. Fanger, C. R. Maliszewski, K. Schooley, and T. S. Griffith, “Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),” The Journal of Experimental Medicine, vol. 190, no. 8, pp. 1155–1164, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Schmitz, S. Zhao, Y. Deuse et al., “Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity,” The Journal of Immunology, vol. 174, no. 7, pp. 4127–4134, 2005. View at Google Scholar · View at Scopus
  20. G. Stary, C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl, “Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells,” The Journal of Experimental Medicine, vol. 204, no. 6, pp. 1441–1451, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. Banchereau and A. K. Palucka, “Dendritic cells as therapeutic vaccines against cancer,” Nature Reviews Immunology, vol. 5, no. 4, pp. 296–306, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. E. Gilboa, “DC-based cancer vaccines,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1195–1203, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. B.-H. Xue, Y. Zhang, J. A. Sosman, and D. J. Peace, “Induction of human cytotoxic T lymphocytes specific for prostate- specific antigen,” Prostate, vol. 30, no. 2, pp. 73–78, 1997. View at Publisher · View at Google Scholar
  24. S. Perambakam, B.-H. Xue, J. A. Sosman, and D. J. Peace, “Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer,” Cancer Immunology, Immunotherapy, vol. 51, no. 5, pp. 263–270, 2002. View at Publisher · View at Google Scholar · View at PubMed
  25. P. Correale, K. Walmsley, C. Nieroda et al., “In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen,” Journal of the National Cancer Institute, vol. 89, no. 4, pp. 293–300, 1997. View at Google Scholar
  26. P. Correale, K. Walmsley, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang, “Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide,” The Journal of Immunology, vol. 161, no. 6, pp. 3186–3194, 1998. View at Google Scholar
  27. A. Heiser, P. Dahm, D. R. Yancey et al., “Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro,” The Journal of Immunology, vol. 164, no. 10, pp. 5508–5514, 2000. View at Google Scholar
  28. B. Tjoa, A. Boynton, G. Kenny, H. Ragde, S. L. Misrock, and G. Murphy, “Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity,” Prostate, vol. 28, no. 1, pp. 65–69, 1996. View at Google Scholar
  29. G. P. Murphy, B. Tjoa, H. Ragde, G. Kenny, and A. Boynton, “Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen,” Prostate, vol. 29, no. 6, pp. 371–380, 1996. View at Publisher · View at Google Scholar
  30. M. V. Peshwa, J. D. Shi, C. Ruegg, R. Laus, and W. C. A. Van Schooten, “Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide,” Prostate, vol. 36, no. 2, pp. 129–138, 1998. View at Publisher · View at Google Scholar
  31. J. Dannull, P.-A. Diener, L. Prikler et al., “Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer,” Cancer Research, vol. 60, no. 19, pp. 5522–5528, 2000. View at Google Scholar
  32. A. Kiessling, M. Schmitz, S. Stevanovic et al., “Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients,” International Journal of Cancer, vol. 102, no. 4, pp. 390–397, 2002. View at Publisher · View at Google Scholar · View at PubMed
  33. A. Kiessling, S. Stevanovic, S. Füssel et al., “Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein,” British Journal of Cancer, vol. 90, no. 5, pp. 1034–1040, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Kiessling, S. Füssel, M. Schmitz et al., “Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8,” Prostate, vol. 56, no. 4, pp. 270–279, 2003. View at Publisher · View at Google Scholar · View at PubMed
  35. R. H. Vonderheide, W. C. Hahn, J. L. Schultze, and L. M. Nadler, “The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes,” Immunity, vol. 10, no. 6, pp. 673–679, 1999. View at Publisher · View at Google Scholar
  36. B. Minev, J. Hipp, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti, “Cytotoxic T cell immunity against telomerase reverse transcriptase in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4796–4801, 2000. View at Publisher · View at Google Scholar · View at PubMed
  37. M. Schmitz, P. Diestelkoetter, B. Weigle et al., “Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides,” Cancer Research, vol. 60, no. 17, pp. 4845–4849, 2000. View at Google Scholar
  38. M. H. Andersen, L. O. Pedersen, J. C. Becket, and P. Thor Straten, “Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients,” Cancer Research, vol. 61, no. 3, pp. 869–872, 2001. View at Google Scholar
  39. A. Lundwall and H. Lilja, “Molecular cloning of human prostate specific antigen cDNA,” FEBS Letters, vol. 214, no. 2, pp. 317–322, 1987. View at Google Scholar
  40. J. E. Oesterling, “Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate,” The Journal of Urology, vol. 145, no. 5, pp. 907–923, 1991. View at Google Scholar
  41. S. P. Balk, Y.-J. Ko, and G. J. Bubley, “Biology of prostate-specific antigen,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 383–391, 2003. View at Publisher · View at Google Scholar
  42. S. J. Freedland, J. M. Hotaling, N. J. Fitzsimons et al., “PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes—results from the SEARCH database,” European Urology, vol. 53, no. 4, pp. 758–766, 2008. View at Publisher · View at Google Scholar · View at PubMed
  43. H. Terasawa, K.-Y. Tsang, J. Gulley, P. Arlen, and J. Schlom, “Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen,” Clinical Cancer Research, vol. 8, no. 1, pp. 41–53, 2002. View at Google Scholar
  44. G. P. Murphy, A.-A. A. Elgamal, S. L. Su, D. G. Bostwick, and E. H. Holmes, “Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen,” Cancer, vol. 83, no. 11, pp. 2259–2269, 1998. View at Publisher · View at Google Scholar
  45. M. Kawakami and J. Nakayama, “Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization,” Cancer Research, vol. 57, no. 12, pp. 2321–2324, 1997. View at Google Scholar
  46. T. Solin, M. Kontturi, R. Pohlmann, and P. Vihko, “Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses,” Biochimica et Biophysica Acta, vol. 1048, no. 1, pp. 72–77, 1990. View at Publisher · View at Google Scholar
  47. R. E. Reiter, Z. Gu, T. Watabe et al., “Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 4, pp. 1735–1740, 1998. View at Publisher · View at Google Scholar
  48. Z. Gu, G. Thomas, J. Yamashiro et al., “Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer,” Oncogene, vol. 19, no. 10, pp. 1288–1296, 2000. View at Google Scholar
  49. J. Xu, M. Kalos, J. A. Stolk et al., “Identification and characterization of prostein, a novel prostate-specific protein,” Cancer Research, vol. 61, no. 4, pp. 1563–1568, 2001. View at Google Scholar
  50. M. Kalos, J. Askaa, B. L. Hylander et al., “Prostein expression is highly restricted to normal and malignant prostate tissues,” Prostate, vol. 60, no. 3, pp. 246–256, 2004. View at Publisher · View at Google Scholar · View at PubMed
  51. L. Tsavaler, M. H. Shapero, S. Morkowski, and R. Laus, “Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins,” Cancer Research, vol. 61, no. 9, pp. 3760–3769, 2001. View at Google Scholar
  52. N. W. Kim, M. A. Piatyszek, K. R. Prowse et al., “Specific association of human telomerase activity with immortal cells and cancer,” Science, vol. 266, no. 5193, pp. 2011–2015, 1994. View at Google Scholar
  53. M. Thorn, M. Wang, H. Kløverpris et al., “Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope,” Cancer Immunology, Immunotherapy, vol. 56, no. 11, pp. 1755–1763, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. G. Ambrosini, C. Adida, and D. C. Altieri, “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,” Nature Medicine, vol. 3, no. 8, pp. 917–921, 1997. View at Publisher · View at Google Scholar
  55. H. Koike, Y. Sekine, M. Kamiya, H. Nakazato, and K. Suzuki, “Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer,” Urology, vol. 72, no. 6, pp. 1229–1233, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. J. I. Mayordomo, T. Zorina, W. J. Storkus et al., “Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity,” Nature Medicine, vol. 1, no. 12, pp. 1297–1302, 1995. View at Google Scholar · View at Scopus
  57. S. K. Nair, A. Heiser, D. Boczkowski et al., “Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells,” Nature Medicine, vol. 6, no. 9, pp. 1011–1017, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. F. J. Hsu, C. Benike, F. Fagnoni et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nature Medicine, vol. 2, no. 1, pp. 52–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. F. O. Nestle, S. Alijagic, M. Gilliet et al., “Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,” Nature Medicine, vol. 4, no. 3, pp. 328–332, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Thurner, I. Haendle, C. Röder et al., “Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,” The Journal of Experimental Medicine, vol. 190, no. 11, pp. 1669–1678, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Wierecky, M. R. Müller, S. Wirths et al., “Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients,” Cancer Research, vol. 66, no. 11, pp. 5910–5918, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. B. A. Tjoa, S. J. Erickson, V. A. Bowes et al., “Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides,” Prostate, vol. 32, no. 4, pp. 272–278, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. B. A. Tjoa, S. J. Simmons, V. A. Bowes et al., “Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides,” Prostate, vol. 36, no. 1, pp. 39–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. R. H. Vonderheide, S. M. Domchek, J. L. Schultze et al., “Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes,” Clinical Cancer Research, vol. 10, no. 3, pp. 828–839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Fuessel, A. Meye, M. Schmitz et al., “Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial,” Prostate, vol. 66, no. 8, pp. 811–821, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. Y. Waeckerle-Men, E. Uetz-Von Allmen, M. Fopp et al., “Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma,” Cancer Immunology, Immunotherapy, vol. 55, no. 12, pp. 1524–1533, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. A.-K. Thomas-Kaskel, R. Zeiser, R. Jochim et al., “Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival,” International Journal of Cancer, vol. 119, no. 10, pp. 2428–2434, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. B. Hildenbrand, B. Sauer, O. Kalis et al., “Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—a pilot study,” Prostate, vol. 67, no. 5, pp. 500–508, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. L. Fong, D. Brockstedt, C. Benike et al., “Dendritic cell-based xenoantigen vaccination for prostate cancer Immunotherapy,” The Journal of Immunology, vol. 167, no. 12, pp. 7150–7156, 2001. View at Google Scholar · View at Scopus
  70. B. Barrou, G. Benoît, M. Ouldkaci et al., “Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA,” Cancer Immunology, Immunotherapy, vol. 53, no. 5, pp. 453–460, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. E. J. Small, P. Fratesi, D. M. Reese et al., “Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells,” Journal of Clinical Oncology, vol. 18, no. 23, pp. 3894–3903, 2000. View at Google Scholar · View at Scopus
  72. P. A. Burch, G. A. Croghan, D. A. Gastineau et al., “Immunotherapy (APC8015, provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial,” Prostate, vol. 60, no. 3, pp. 197–204, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. B. I. Rini, V. Weinberg, L. Fong, S. Conry, R. M. Hershberg, and E. J. Small, “Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy,” Cancer, vol. 107, no. 1, pp. 67–74, 2006. View at Publisher · View at Google Scholar · View at PubMed
  74. E. J. Small, P. F. Schellhammer, C. S. Higano et al., “Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3089–3094, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. C. S. Higano, P. F. Schellhammer, E. J. Small et al., “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer,” Cancer, vol. 115, no. 16, pp. 3670–3679, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistent prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Google Scholar
  77. A. Heiser, D. Coleman, J. Dannull et al., “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors,” The Journal of Clinical Investigation, vol. 109, no. 3, pp. 409–417, 2002. View at Publisher · View at Google Scholar
  78. Z. Su, J. Dannull, B. K. Yang et al., “Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer,” The Journal of Immunology, vol. 174, no. 6, pp. 3798–3807, 2005. View at Google Scholar · View at Scopus
  79. L. J. Mu, J. A. Kyte, G. Kvalheim et al., “Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients,” British Journal of Cancer, vol. 93, no. 7, pp. 749–756, 2005. View at Publisher · View at Google Scholar · View at PubMed
  80. C. S. Higano, N. J. Vogelzang, J. A. Sosman, A. Feng, D. Caron, and E. J. Small, “Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-Refractory prostate cancer,” Clinical Cancer Research, vol. 10, no. 4, pp. 1219–1225, 2004. View at Publisher · View at Google Scholar